Belite Bio (NASDAQ: BLTE) files Form 6-K on Q3 2025 results

Rhea-AI Filing Summary

Belite Bio, Inc furnished a Form 6-K to provide investors with a press release titled “Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update.” The press release is attached as Exhibit 99.1 and incorporated by reference, meaning its contents are formally included in Belite Bio’s effective Securities Act registration statements from the filing date unless later superseded.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-41359

Belite Bio, Inc

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of Registrant´s name into English)

12750 High Bluff Drive Suite 475,

San Diego, CA 92130

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x  Form 40-F ¨

On November 10, 2025, Belite Bio, Inc issued a press release entitled “Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update.” A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This Report on Form 6-K shall be deemed to be incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933 and shall be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit 99.1 — Press Release

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Belite Bio, Inc
	By:	/s/ Yu-Hsin Lin
	Name:	Yu-Hsin Lin
	Title:	Chief Executive Officer and Chairman

Date: November 10, 2025

FAQ

What did Belite Bio (BLTE) disclose in this Form 6-K?

Belite Bio, Inc disclosed that it issued a press release titled “Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update,” which is attached as Exhibit 99.1 and incorporated by reference.

Does this Belite Bio (BLTE) Form 6-K include the full Q3 2025 financial results?

The Form 6-K itself states that the Q3 2025 financial results and corporate update are contained in an attached press release, filed as Exhibit 99.1 and incorporated by reference.

How is this Belite Bio (BLTE) Form 6-K used in its registration statements?

The Form 6-K states it will be incorporated by reference into all effective Belite Bio registration statements under the Securities Act of 1933 and will form part of them from the filing date, unless later superseded.

Who signed Belite Bio’s November 2025 Form 6-K?

The Form 6-K was signed on behalf of Belite Bio, Inc by Yu-Hsin Lin, who is identified as Chief Executive Officer and Chairman, dated November 10, 2025.

What exhibit is attached to this Belite Bio (BLTE) Form 6-K?

The filing includes one exhibit, listed as Exhibit 99.1, which is the press release titled “Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update.”